ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Free Trade Agreements, including but not limited to: Colombia, Panama, and Korea Implementation of the Peru Trade Promotion Agreement Special 301 Report Any matters related to international activities with regard to access of generic medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN D JAEGER | — |
| LISA LAYMAN | — |
| JASON R MONEY | — |
Copyright/Patent/Trademark CPT
Patent Reform, including but not limited to: S.1145, S.3600, and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report International Intellectual Property Issues Patent Process Issues, including but not limited to: S.3560, H.R.1778, and H.R.6344 Any other matter that relates to acess to generic drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN D JAEGER | — |
| LISA LAYMAN | — |
| JASON R MONEY | — |
Medicare/Medicaid MMM
Medicaid Reimbursement Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs Average Manufacture Price (AMP)/AMP Publication such as H.R.6331
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN D JAEGER | — |
| LISA LAYMAN | — |
| JASON R MONEY | — |
Budget/Appropriations BUD
FDA Congressional Appropriations, including but not limited to: H.R.2638 and H.R.2642 (Emergency Supplemental Bill) Generic Drug User Fees Funding for FDA, including but not limited to: any proposal relating to funding for the Office of Generic Drugs FY2009 and 2010 Presidential Budget Request
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN D JAEGER | — |
| LISA LAYMAN | — |
| JASON R MONEY | — |
Pharmacy PHA
Generic Biologics, including but not limited to: S.623, S.1505, S.1695, H.R.1038, H.R.1956, and H.R.5629 Prescription Drug Safety Food and Drug Administration Act of 2007 (H.R.3580): any parts relating to access to generic drugs and the impact and marketing of prescription drugs Citizen Petitions, including but not limited to: S.25 and S.1088 Counterfeit Drugs/Import Safety/Pedigree including but not limited to: S.3409 and H.R.5839 Electronic Prescribing Authorized Generics including but not limited to: S.2408 and H.R.4296 Prescription Drug Importation/Re-Importation Any other matters that relate to access to generic drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN D JAEGER | — |
| LISA LAYMAN | — |
| JASON R MONEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.